Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus, DiscoveRx Ink Co-Marketing Agreement

NEW YORK (GenomeWeb News) – BioFocus and DiscoveRx have signed a co-marketing pact that allows BioFocus to offer screening services using DiscoveRx's assay technologies, BioFocus said today.

Under the agreement, BioFocus, based in Saffron Walden, UK, will offer to its customers DiscoverX's PathHunter beta-arrestin GPCR assays, HitHunter cAMP assays, and associated cell lines.

"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform,” Chris Newton, senior vice president at BioFocus, said in a statement.

Financial terms of the agreement were disclosed.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.